Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study
@article{Goldberg2010ClinicalTT, title={Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study}, author={Michael R Goldberg and Y.‐P. Li and John F. Johanson and A W Mangel and Michael M. Kitt and David T. Beattie and Kathryn E. Kersey and Oranee Daniels}, journal={Alimentary Pharmacology \& Therapeutics}, year={2010}, volume={32} }
Aliment Pharmacol Ther 2010; 32: 1102–1112
103 Citations
Systematic review with meta‐analysis: highly selective 5‐HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation
- PsychologyAlimentary pharmacology & therapeutics
- 2014
Highly selective 5‐HT4 agonists have been suggested for the treatment of chronic constipation and have shown promising results in animals and humans.
Defining a responder in treatment trials for chronic idiopathic constipation
- MedicineAlimentary pharmacology & therapeutics
- 2011
This study demonstrated a significant increase in average number of weekly spontaneous bowel movements from baseline with velusetrag compared with placebo, after 4 weeks of therapy, and utilised less stringent primary endpoints than other recent treatment trials in CIC, although the authors justify adequately why these were not used.
Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double‐blind, randomised, placebo‐controlled, phase 2 study
- MedicineAlimentary pharmacology & therapeutics
- 2021
Velusetrag—a potent, selective, pan‐gastrointestinal 5‐hydroxytryptamine type 4 receptor agonist—is under investigation for treatment of GI motility disorders including gastroparesis.
New treatment options for chronic constipation: mechanisms, efficacy and safety.
- Medicine, BiologyCanadian journal of gastroenterology = Journal canadien de gastroenterologie
- 2011
The present review has several objectives, the first of which is to review the pharmacology and selectivity of serotonergic agents to contrast the older serotonergic agents (which were withdrawn…
Current developments in pharmacological therapeutics for chronic constipation
- Medicine, BiologyActa pharmaceutica Sinica. B
- 2015
Aspects of functional constipation : a trial of an opioid antagonist as a treatment and an investigation of the colonic microbiota associated with the illness
- Medicine, Biology
- 2014
Differences in the colonic microbiota in FC warrant further investigation to see how it is implicated in the pathophysiology of FC and cannot be recommended in this group of patients.
Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials
- Medicine, PsychologyDigestive Diseases and Sciences
- 2016
The integrated analysis demonstrates the efficacy and safety of prucalopride in the treatment of CC in men and women.
Current and future therapies for chronic constipation.
- Medicine, BiologyBest practice & research. Clinical gastroenterology
- 2011
YH12852, a Potent and Selective Receptor Agonist of 5‐hydroxytryptamine, Increased Gastrointestinal Motility in Healthy Volunteers and Patients With Functional Constipation
- MedicineClinical and translational science
- 2020
YH12852 was safe and well‐tolerated up to 3 mg and showed nearly dose proportional PKs, and can be developed as an effective treatment option for GI motility disorders, including functional constipation.
References
SHOWING 1-10 OF 40 REFERENCES
Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12‐week, randomized, double‐blind, placebo‐controlled study
- MedicineAlimentary pharmacology & therapeutics
- 2009
This study focuses on the treatment of chronic constipation in women with a history of diarrhea and its role in the quality of life.
Prucalopride, a systemic enterokinetic, for the treatment of constipation
- MedicineAlimentary pharmacology & therapeutics
- 2002
An alternative therapeutic approach is to target serotonin‐4 receptors, which are involved in initiating peristalsis, and it is shown that these receptors are activated by laxatives but are not involved in causing constipation.
Tegaserod, a 5‐HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects
- Medicine, BiologyAlimentary pharmacology & therapeutics
- 2001
Serotonin and its type‐4 (5‐hydroxytryptamine4) receptor play a major role in the physiology of the gastrointestinal tract and the effect of intravenous and/or oral tegaserod on gastric emptying, small bowel transit and colonic transit in humans is studied.
Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial.
- MedicineClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
- 2004
Prucalopride Is Effective in Patients with Severe Chronic Constipation in Whom Laxatives Fail to Provide Adequate Relief
- MedicineDigestion
- 2003
Once-daily prucalopride 4 mg for 4 weeks is effective and well tolerated in patients with severe CC, and improves whole gut transit, reducing straining, softening stools and reducing time to first bowel movement.
Efficacy of linaclotide for patients with chronic constipation.
- MedicineGastroenterology
- 2010
Linaclotide therapy was associated with few adverse events and produced rapid and sustained improvement of bowel habits, abdominal symptoms, global relief, and quality of life in patients with chronic constipation.
A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation
- MedicineGut
- 2005
Tegaserod provides rapid and sustained relief of IBS-C symptoms both during first and repeated treatment and produced greater satisfaction, work productivity, and improved quality of life than placebo (p<0.05).
Effects of Velusetrag (TD‐5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation
- MedicineNeurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
- 2010
Pharmacokinetics studies showed dose proportionality in health, and no significant differences between health and chronic constipation with a 15’mg oral dose of Velusetrag, and further studies of its potential as a gastrointestinal and colonic prokinetic are warranted.
Chronic constipation: a survey of the patient perspective
- MedicineAlimentary pharmacology & therapeutics
- 2007
Background Constipation is a common, often chronic, gastrointestinal motility disorder characterized by such symptoms as straining, hard stool, and infrequent defecation. Published literature is…
Efficacy and Safety of Traditional Medical Therapies for Chronic Constipation: Systematic Review
- MedicineThe American Journal of Gastroenterology
- 2005
There is good evidence to support the use of PEG, tegaserod, lactulose, and psyllium and recommendations were made regarding their use following the United States Preventive Services Task Force guidelines.